Filter
99
Filtered Results: 99
Text search:
heterologous
Featured
Recommendations
9
New Publications
14
Language
Document type
Guidelines
39
No document type
32
Studies & Reports
12
Manuals
5
Fact sheets
5
Strategic & Response Plan
4
Situation Updates
1
Infographics
1
Countries / Regions
Brazil
8
India
6
Argentina
5
Africa
3
Latin America and the Carribbean
3
South Africa
3
Nigeria
2
Mozambique
2
Paraguay
2
Bolivia
2
Russia
2
Chile
1
Philippines
1
Global
1
Asia
1
Tanzania
1
Germany
1
East and Southern Africa
1
Uganda
1
Indonesia
1
Ecuador
1
Authors & Publishers
Publication Years
Category
Guidelines
23
COVID-19
22
Rabies
4
Policies
3
Non-communicable Diseases
3
Virology
2
Malaria
2
Paediatrics
1
Clinical Training
1
Hematology
1
Vaccine-preventable Diseases
1
Yellow Fever
1
Policies & Guidelines HIV & TB
1
Drugs & Medical Equipment
1
Studies & Reports
1
NTDs & Others
1
Dengue
1
Parasitology
1
Disease Prevention & Control
1
Toolboxes
Country specific documents
13
Inactivated COVID-19 Vaccines
10
Booster Doses
9
Immunization Guidelines
8
Biontech/Pfizer Comirnaty
7
Vaxzevria (Astra Zeneca)
6
Moderna
4
Access & Strategy
3
Research & Access
3
Fair Allocation & Ethical Aspects
2
Johnson & Johnson
2
Covaxin
2
Clinical Aspects & Diagnostics
2
Studies & Reports
2
Zika
2
Laboratory & Diagnostics
2
Assessment & Studies
1
Vaccines & Immunization
1
Yellow Fever
1
Pediatrics
1
Dengue
1
HIV
1
TB
1
IACAPAP International Association for Child and Adolescent Psychiatry and Allied Professions
1
Children/Adolescents Mental Disorders
1
Vaccination
1
Children
1
Clinical Guidelines
1
COVID-19
1
For Parents & Children
1
For Older People
1
Communication Material
1
Dashboards & Resource Platforms
1
SARS-CoV-2 Variants
1
Vector-based Vacines General
1
Sputnik V
1
Chile
1
Traditional & Herbal Medicines
1
Zoonoses
1
MPOX - Monkeypox
1
Clinical Aspects & Diagnostics
1
Statistics & Facts
1
Studies & Reports
1
Studies & Reports
1
General Information & Methodology
1
Prevention & Strategies
1
Neurological Disorders
1
Food & Nutrition
1
Neurological disorders, Others
1
These WHO interim recommendations on the use of the Astra Zeneca – Oxford University AZD1222 vaccine against Covid-19 were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenc...
6 June 2022
These WHO interim recommendations on the use of the Janssen Ad26.COV2.S (COVID-19) vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document referenced below.
Th...
Bisher hat die STIKO empfohlen, dass alle im Ausland mit einem nicht in der EU zugelassenen Impfstoff geimpften Personen eine erneute Impfserie mit einem in der EU zugelassenen Impfstoff erhalten sollen. Ziel der im Epidemiologischen Bulletin 13/2022 veröffentlichten aktualisierten COVID-19-Impfemp...
orientaciones provisionales, primera publicación: 24 de mayo de 2021, actualización: 21 de octubre de 2021, actualización: 15 de marzo de 2022
These WHO interim recommendations for use of the BBV152 COVAXIN vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
This document has been ...
These WHO interim recommendations for use of the COVID-19 vaccine BIBP produced by Sinopharm were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Th...
27 September 2022
These WHO interim recommendations for use of the Novavax NVX-CoV2373 vaccine were developed on the basis of advice issued by the Strategic Advisory Group of Experts on Immunization (SAGE) and the evidence summary included in the background document and annexes referenced below.
Data for Action March 2022, Issue 5
first issued 18 August 2022
Declarations of interests were collected from all external contributors and assessed for any conflicts of interest. Summaries of the reported interests can be found on the SAGE meeting website and SAGE Covid-19 Working Group webpage. This guidance should be considered along with the broader COVID-...
Report of the WHO/Bill & Melinda Gates Foundation Consultation. The Consultation was organized back-to-back with the first annual meeting of the International Coordinating Group of the BMGF-funded project for human and dog rabies elimination in developing countries, held at WHO headquarters, Geneva,...
Arsenical monotherapies were previously very successful for treating human African trypanosomiasis (HAT).
Melarsoprol resistance emerged as early as the 1970s and was widespread by the late 1990s.
Melarsoprol resistance represents the only example of widespread drug resistance in HAT patients wher...
Rabies has an enormous impact on both agriculture and conservation biology, but its greatest burden is undeniably on public health. As such, routine methods for rapid risk assessment after human exposures to rabies as well as applications for laboratory-based surveillance, production of biologicals ...
Organización Mundial de la Salud. (2022). Recomendaciones provisionales sobre el uso de la vacuna CanSinoBIO Ad5-nCoV-S [recombinante] (Convidecia™) contra la COVID-19: orientaciones provisionales, primera publicación: 19 de mayo de 2022.
In April 2020, Gavi and COVAX joined the Access to COVID-19 Tools Accelerator (ACT-A) to provide equitable global access to COVID-19 vaccines to tackle the pandemic. In June 2020, the Gavi COVAX Advance Market Commitment (AMC) was launched to finance equitable access in 92 lower-income countries. Si...
Buruli ulcer (BU) is a bacterial skin infection that is caused by Mycobacterium ulcerans and mainly affects people who reside in the rural areas of Africa and in suburban and beach resort communities in Australia.
